Fiche société
Eli Lilly and Company
Traitements, essais et publications liés.
Traitements39programmes
Essais33liés
Publications0liées
SourceDBlocale
Traitements
39| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| BimagrumabThis study will look at how bimagrumab affects adults who have a type of heart failure called HFpEF (heart failure with preserved ejection fraction), where the heart pumps normally but does not fill with blood as well as it should. Participation in the study will last about 76 weeks. | Insuffisance cardiaque, Maladie coronarienne | Phase 2 | À vérifier | United States, Hungary, Italy, Poland | À vérifier |
| CYP450 Drug CocktailDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | Phase 1 | À vérifier | United States, Canada | À vérifier |
| DonanemabThe main purpose of this study is to evaluate the effects of donanemab (LY3002813) versus placebo in Chinese participants who are at risk for decline of memory, language and physical ability to perform activities of daily living from Alzheimer's disease (AD). The study drug will be administered intravenously (IV) (into a vein in the arm). The study will last up to approximately 156 weeks, excluding screening. | Alzheimer | Phase 3 | À vérifier | United States, Japan, Puerto Rico | À vérifier |
| Flortaucipir F18The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD. The study will be comprised of two parts, A and B. Each enrolled participant in Part A will receive a single dose of LY3954068 or placebo (no active drug) given into the spinal fluid. Each participant in Part B will receive up to 4 doses of either LY3954068 or placebo administered into the spinal fluid. Participants may have the opportunity to join an optional bridging period to a separate potential study where participants would receive LY3954068. The study will last up to approximately 45 weeks for Part A, and 100 weeks for Part B, including the screening period. | Alzheimer | Phase 1 | Traitement symptomatique | United States, Japan, United Kingdom | À vérifier |
| LY2216684The primary objective of this study is to confirm that LY2216684 is not an inhibitor of cytochrome P450 1A2 (CYP1A2) in healthy participants using theophylline as a probe substrate for the enzyme. Because LY2216684 has been observed to increase heart rate in some healthy participants, this study will also assess heart rate when coadministered with theophylline. | SEP | Phase 1 | À vérifier | United States | À vérifier |
| LY3295668 ErbumineThe reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma. | Épilepsie | Phase 1 | À vérifier | United States, Australia, Belgium, France, Germany, Italy, Japan, Spain, … | À vérifier |
| LY3439539The purpose of this study is to see how LY3439539 affects certain proteins found in the spinal fluid of participants with Alzheimer's disease. Participation in the study will last approximately 9 months with visits about once a month. | Alzheimer | Phase 1 | À vérifier | United States, Australia, New Zealand, Singapore | À vérifier |
| LY3541860The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better. The study will last about 9 months with additional 6 months follow-up. | SEP | Phase 2 | À vérifier | United States, France, Italy, Latvia, Poland, Slovakia, United Kingdom | À vérifier |
| LY3873862Description non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | Phase 1 | À vérifier | United States, Canada | À vérifier |
| LY3954068The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD. The study will be comprised of two parts, A and B. Each enrolled participant in Part A will receive a single dose of LY3954068 or placebo (no active drug) given into the spinal fluid. Each participant in Part B will receive up to 4 doses of either LY3954068 or placebo administered into the spinal fluid. Participants may have the opportunity to join an optional bridging period to a separate potential study where participants would receive LY3954068. The study will last up to approximately 45 weeks for Part A, and 100 weeks for Part B, including the screening period. | Alzheimer | Phase 1 | Traitement symptomatique | United States, Japan, United Kingdom | À vérifier |
| LY4256984Description non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | Phase 1 | À vérifier | Belgium, Canada, Germany, Netherlands, Spain | À vérifier |
| LY4298445The purpose of this study is to investigate the safety and tolerability of LY4298445 in healthy participants and in participants with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). Participation in the study will last up to approximately 52 weeks. | Lupus | Phase 1 | À vérifier | Australia, China, Japan | À vérifier |
| LY4405094The purpose of this study is to see how safe LY4405094 is and to see how much and how quickly LY4405094 gets into the bloodstream. For healthy participants, the study also looks at how much LY4405094 gets into the fluid around the brain and lasts up to 13 weeks and will include a 4-day stay in the Clinical Research Unit (CRU). For participants with Alzheimer's Disease, the study will also look at levels of a specific Alzheimer's-related protein in the brain and will last up to 25 weeks and will include a 3-day stay in the CRU. | Alzheimer | Phase 1 | À vérifier | United States, China, Japan | À vérifier |
| LY4560736The purpose of this study is to see how safe LY4560736 is and to see how much and how quickly LY4560736 gets into the bloodstream. For healthy participants, the study also looks at how much LY4560736 gets into the brain. This part of the study lasts up to 13 weeks which includes staying in the Clinical Research Unit (CRU) for at least 4 days. This group will include Japanese participants, and the Sponsor may choose to enroll Chinese participants. For participants with Alzheimer's Disease, the study will also look at levels of a specific Alzheimer's-related protein in the brain and will last up to 13 weeks which includes staying in the CRU twice, each lasts about 1 to 2 days. Japanese participants, and potentially Chinese participants, may also be enrolled in this group. | Alzheimer | Phase 1 | À vérifier | United States, China, Japan | À vérifier |
| RetatrutideThe main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor. | Accident vasculaire cérébral, Maladie coronarienne, Maladie rénale chronique | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, … | À vérifier |
| SolanezumabThe purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer Disease \[AD\]). | Alzheimer | Phase 3 | Ralentissement de la progression | United States, Australia, Canada, Japan | À vérifier |
| LY3439539The purpose of this study is to see how LY3439539 affects certain proteins found in the spinal fluid of participants with Alzheimer's disease. Participation in the study will last approximately 9 months with visits about once a month. | Alzheimer | Phase 1 | À vérifier | United States, Australia, New Zealand, Singapore | À vérifier |
| LY4256984Description non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | Phase 1 | À vérifier | Belgium, Canada, Germany, Netherlands, Spain | À vérifier |
| DonanemabThe main purpose of this study is to evaluate the effects of donanemab (LY3002813) versus placebo in Chinese participants who are at risk for decline of memory, language and physical ability to perform activities of daily living from Alzheimer's disease (AD). The study drug will be administered intravenously (IV) (into a vein in the arm). The study will last up to approximately 156 weeks, excluding screening. | Alzheimer | Phase 3 | À vérifier | China | À vérifier |
| DonanemabThe main purpose of this study is to evaluate the effects of donanemab (LY3002813) versus placebo in Chinese participants who are at risk for decline of memory, language and physical ability to perform activities of daily living from Alzheimer's disease (AD). The study drug will be administered intravenously (IV) (into a vein in the arm). The study will last up to approximately 156 weeks, excluding screening. | Alzheimer | Phase 2 | À vérifier | United States, Japan, South Korea, Taiwan | À vérifier |
| LY4256984Description non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | Phase 1 | À vérifier | Belgium, Canada, Germany, Netherlands, Spain | À vérifier |
| SolanezumabThe purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer Disease \[AD\]). | Alzheimer | Phase 3 | Ralentissement de la progression | United States, Australia, Canada, Japan | À vérifier |
| LY4405094The purpose of this study is to see how safe LY4405094 is and to see how much and how quickly LY4405094 gets into the bloodstream. For healthy participants, the study also looks at how much LY4405094 gets into the fluid around the brain and lasts up to 13 weeks and will include a 4-day stay in the Clinical Research Unit (CRU). For participants with Alzheimer's Disease, the study will also look at levels of a specific Alzheimer's-related protein in the brain and will last up to 25 weeks and will include a 3-day stay in the CRU. | Alzheimer | Phase 1 | À vérifier | United States, China, Japan | À vérifier |
| DonanemabThe main purpose of this study is to evaluate the effects of donanemab (LY3002813) versus placebo in Chinese participants who are at risk for decline of memory, language and physical ability to perform activities of daily living from Alzheimer's disease (AD). The study drug will be administered intravenously (IV) (into a vein in the arm). The study will last up to approximately 156 weeks, excluding screening. | Alzheimer | Phase 3 | À vérifier | United States, Australia, Canada, Czechia, Japan, Netherlands, Poland, Puerto Rico, United Kingdom | À vérifier |
| LY4405094The purpose of this study is to see how safe LY4405094 is and to see how much and how quickly LY4405094 gets into the bloodstream. For healthy participants, the study also looks at how much LY4405094 gets into the fluid around the brain and lasts up to 13 weeks and will include a 4-day stay in the Clinical Research Unit (CRU). For participants with Alzheimer's Disease, the study will also look at levels of a specific Alzheimer's-related protein in the brain and will last up to 25 weeks and will include a 3-day stay in the CRU. | Alzheimer | Phase 1 | À vérifier | United States, China, Japan | À vérifier |
| LY3295668 ErbumineThe reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma. | Épilepsie | Phase 1 | À vérifier | United States, Australia, Belgium, France, Germany, Italy, Japan, Spain, United Kingdom | À vérifier |
| DonanemabThe main purpose of this study is to evaluate the effects of donanemab (LY3002813) versus placebo in Chinese participants who are at risk for decline of memory, language and physical ability to perform activities of daily living from Alzheimer's disease (AD). The study drug will be administered intravenously (IV) (into a vein in the arm). The study will last up to approximately 156 weeks, excluding screening. | Alzheimer | Phase 2/3 | À vérifier | Colombia | À vérifier |
| LY4298445The purpose of this study is to investigate the safety and tolerability of LY4298445 in healthy participants and in participants with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). Participation in the study will last up to approximately 52 weeks. | Lupus | Phase 1 | À vérifier | Australia, China, Japan | À vérifier |
| LY2216684The primary objective of this study is to confirm that LY2216684 is not an inhibitor of cytochrome P450 1A2 (CYP1A2) in healthy participants using theophylline as a probe substrate for the enzyme. Because LY2216684 has been observed to increase heart rate in some healthy participants, this study will also assess heart rate when coadministered with theophylline. | SEP | Phase 1 | À vérifier | United States | À vérifier |
| LY3541860The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better. The study will last about 9 months with additional 6 months follow-up. | SEP | Phase 2 | À vérifier | United States, France, Italy, Latvia, Poland, Slovakia, United Kingdom | À vérifier |
| DonanemabThe main purpose of this study is to evaluate the effects of donanemab (LY3002813) versus placebo in Chinese participants who are at risk for decline of memory, language and physical ability to perform activities of daily living from Alzheimer's disease (AD). The study drug will be administered intravenously (IV) (into a vein in the arm). The study will last up to approximately 156 weeks, excluding screening. | Alzheimer | Phase 4 | Traitement symptomatique | India | À vérifier |
| LY4560736The purpose of this study is to see how safe LY4560736 is and to see how much and how quickly LY4560736 gets into the bloodstream. For healthy participants, the study also looks at how much LY4560736 gets into the brain. This part of the study lasts up to 13 weeks which includes staying in the Clinical Research Unit (CRU) for at least 4 days. This group will include Japanese participants, and the Sponsor may choose to enroll Chinese participants. For participants with Alzheimer's Disease, the study will also look at levels of a specific Alzheimer's-related protein in the brain and will last up to 13 weeks which includes staying in the CRU twice, each lasts about 1 to 2 days. Japanese participants, and potentially Chinese participants, may also be enrolled in this group. | Alzheimer | Phase 1 | À vérifier | United States, China, Japan | À vérifier |
| DonanemabThe main purpose of this study is to evaluate the effects of donanemab (LY3002813) versus placebo in Chinese participants who are at risk for decline of memory, language and physical ability to perform activities of daily living from Alzheimer's disease (AD). The study drug will be administered intravenously (IV) (into a vein in the arm). The study will last up to approximately 156 weeks, excluding screening. | Alzheimer | À vérifier | Traitement symptomatique | United States | À vérifier |
| RetatrutideThe main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor. | Maladie rénale chronique | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, India, Israel, Italy, Mexico, Netherlands, New Zealand, Poland, … | À vérifier |
| LY3873862Description non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | Phase 1 | À vérifier | United States, Canada | À vérifier |
| LY3954068The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD. The study will be comprised of two parts, A and B. Each enrolled participant in Part A will receive a single dose of LY3954068 or placebo (no active drug) given into the spinal fluid. Each participant in Part B will receive up to 4 doses of either LY3954068 or placebo administered into the spinal fluid. Participants may have the opportunity to join an optional bridging period to a separate potential study where participants would receive LY3954068. The study will last up to approximately 45 weeks for Part A, and 100 weeks for Part B, including the screening period. | Alzheimer | Phase 1 | Traitement symptomatique | United States, Japan, United Kingdom | À vérifier |
| DonanemabThe main purpose of this study is to evaluate the effects of donanemab (LY3002813) versus placebo in Chinese participants who are at risk for decline of memory, language and physical ability to perform activities of daily living from Alzheimer's disease (AD). The study drug will be administered intravenously (IV) (into a vein in the arm). The study will last up to approximately 156 weeks, excluding screening. | Alzheimer | Phase 3 | À vérifier | United States, Japan, Puerto Rico | À vérifier |
| LY4256984Description non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | Phase 1 | À vérifier | Belgium, Canada, Germany, Netherlands, Spain | À vérifier |
| BimagrumabThis study will look at how bimagrumab affects adults who have a type of heart failure called HFpEF (heart failure with preserved ejection fraction), where the heart pumps normally but does not fill with blood as well as it should. Participation in the study will last about 76 weeks. | Maladie coronarienne | Phase 2 | À vérifier | United States, Hungary, Italy, Poland | À vérifier |
Essais cliniques
33| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Bimagrumab | Maladie coronarienne | Phase 2 | NCT07920887 | ACTIVATE-HFpEF — A Study of Bimagrumab in Participants With HFpEF | NOT_YET_RECRUITING |
| LY4256984 | Sclérose latérale amyotrophique | Phase 1 | NCT07100119 | A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis | RECRUITING |
| Donanemab | Alzheimer | Phase 3 | NCT07602582 | A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT). | RECRUITING |
| LY3954068 | Alzheimer | Phase 1 | NCT06297590 | A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease | RECRUITING |
| LY3873862 | Sclérose latérale amyotrophique | Phase 1 | NCT07883590 | A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS). | NOT_YET_RECRUITING |
| Retatrutide | Maladie rénale chronique | Phase 3 | NCT06383390 | The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) | ACTIVE_NOT_RECRUITING |
| Donanemab | Alzheimer | À vérifier | NCT06566170 | A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease | RECRUITING |
| LY4560736 | Alzheimer | Phase 1 | NCT07843459 | A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD) | NOT_YET_RECRUITING |
| Donanemab | Alzheimer | Phase 4 | NCT07838155 | A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease | NOT_YET_RECRUITING |
| LY3541860 | SEP | Phase 2 | NCT06220669 | A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis | TERMINATED |
| LY2216684 | SEP | Phase 1 | NCT01263106 | A Study of LY2216684 and Theophylline in Healthy Subjects | COMPLETED |
| LY4298445 | Lupus | Phase 1 | NCT07276958 | A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA) | RECRUITING |
| Lasmiditan | Migraine | Phase 3 | NCT04396236 | PIONEER-PEDS1 — A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine | TERMINATED |
| Donanemab | Alzheimer | Phase 2/3 | NCT06996730 | A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease | RECRUITING |
| Clazakizumab | Maladie rénale chronique | Phase 2 | NCT07783802 | CLARITY-CRP — A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event | RECRUITING |
| LY3295668 Erbumine | Épilepsie | Phase 1 | NCT04106219 | A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma | ACTIVE_NOT_RECRUITING |
| LY4405094 | Alzheimer | Phase 1 | NCT07787169 | A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease | RECRUITING |
| Donanemab | Alzheimer | Phase 3 | NCT04437511 | A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) | ACTIVE_NOT_RECRUITING |
| LY4405094 | Alzheimer | Phase 1 | NCT07787182 | A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease | RECRUITING |
| Lasmiditan | Migraine | Phase 2 | NCT03962738 | MONONOFU — A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine | COMPLETED |
| Galcanezumab | Migraine | Phase 3 | NCT03963232 | PERSIST — A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine | COMPLETED |
| Galcanezumab | Migraine | Phase 4 | NCT05127486 | CHALLENGE-MIG — A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine | COMPLETED |
| Galcanezumab | Migraine | Phase 3 | NCT04616326 | REBUILD-2 — A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine | ACTIVE_NOT_RECRUITING |
| Lasmiditan | Migraine | Phase 3 | NCT04396574 | PIONEER-PEDS2 — A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine | TERMINATED |
| Solanezumab | Alzheimer | Phase 3 | NCT02008357 | A4 — Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss | COMPLETED |
| LY4256984 | Sclérose latérale amyotrophique | Phase 1 | NCT07571200 | A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS) | RECRUITING |
| Donanemab | Alzheimer | Phase 2 | NCT07589595 | A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) | RECRUITING |
| Donanemab | Alzheimer | Phase 3 | NCT07571161 | Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease | RECRUITING |
| LY4256984 | Sclérose latérale amyotrophique | Phase 1 | NCT07571174 | A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis | RECRUITING |
| Galcanezumab | Migraine | Phase 3 | NCT03432286 | REBUILD-1 — A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine | ACTIVE_NOT_RECRUITING |
| LY3439539 | Alzheimer | Phase 1 | NCT07598370 | A Study of LY3439539 in Participants With Alzheimer's Disease | RECRUITING |
| Galcanezumab | Migraine | Phase 3 | NCT02614261 | REGAIN — Evaluation of Galcanezumab in the Prevention of Chronic Migraine | COMPLETED |
| Lasmiditan | Migraine | Phase 2 | NCT00883051 | Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment | COMPLETED |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||